The retinal ganglion cell layer reflects neurodegenerative changes in cognitively unimpaired individuals.
Alzheimer’s disease
Amyloid
Ganglion cell layer
Hippocampal volume
Neurodegeneration
Optical coherence tomography
Retinal nerve fiber layer
Tau
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
21 04 2022
21 04 2022
Historique:
received:
30
07
2021
accepted:
04
04
2022
entrez:
22
4
2022
pubmed:
23
4
2022
medline:
26
4
2022
Statut:
epublish
Résumé
To evaluate a wide range of optical coherence tomography (OCT) parameters for possible application as a screening tool for cognitively healthy individuals at risk of Alzheimer's disease (AD), assessing the potential relationship with established cerebrospinal fluid (CSF) core AD biomarkers and magnetic resonance imaging (MRI). We studied 99 participants from the Valdecilla Study for Memory and Brain Aging. This is a prospective cohort for multimodal biomarker discovery and validation that includes participants older than 55 years without dementia. Participants received a comprehensive neuropsychological battery and underwent structural 3-T brain MRI, lumbar puncture for CSF biomarkers (phosphorylated-181-Tau (pTau), total Tau (tTau), beta-amyloid 1-42 (Aβ 1-42), and beta-amyloid 1-40 (Aβ 1-40)). All individuals underwent OCT to measure the retinal ganglion cell layer (GCL), the retinal nerve fiber layer (RFNL), the Bruch's membrane opening-minimum rim width (BMO-MRW), and choroidal thickness (CT). In the first stage, we performed a univariate analysis, using Student's t-test. In the second stage, we performed a multivariate analysis including only those OCT parameters that discriminated at a nominal level, between positive/negative biomarkers in stage 1. We found significant differences between the OCT measurements of pTau- and tTau-positive individuals compared with those who were negative for these markers, most notably that the GCL and the RNFL were thinner in the former. In stage 2, our dependent variables were the quantitative values of CSF markers and the hippocampal volume. The Aβ 1-42/40 ratio did not show a significant correlation with OCT measurements while the associations between pTau and tTau with GCL were statistically significant, especially in the temporal region of the macula. Besides, the multivariate analysis showed a significant correlation between hippocampal volume with GCL and RNFL. However, after false discovery rate correction, only the associations with hippocampal volume remained significant. We found a significant correlation between Tau (pTau) and neurodegeneration biomarkers (tTau and hippocampus volume) with GCL degeneration and, to a lesser degree, with damage in RFNL. OCT analysis constitutes a non-invasive and unexpensive biomarker that allows the detection of neurodegeneration in cognitively asymptomatic individuals.
Sections du résumé
BACKGROUND
To evaluate a wide range of optical coherence tomography (OCT) parameters for possible application as a screening tool for cognitively healthy individuals at risk of Alzheimer's disease (AD), assessing the potential relationship with established cerebrospinal fluid (CSF) core AD biomarkers and magnetic resonance imaging (MRI).
METHODS
We studied 99 participants from the Valdecilla Study for Memory and Brain Aging. This is a prospective cohort for multimodal biomarker discovery and validation that includes participants older than 55 years without dementia. Participants received a comprehensive neuropsychological battery and underwent structural 3-T brain MRI, lumbar puncture for CSF biomarkers (phosphorylated-181-Tau (pTau), total Tau (tTau), beta-amyloid 1-42 (Aβ 1-42), and beta-amyloid 1-40 (Aβ 1-40)). All individuals underwent OCT to measure the retinal ganglion cell layer (GCL), the retinal nerve fiber layer (RFNL), the Bruch's membrane opening-minimum rim width (BMO-MRW), and choroidal thickness (CT). In the first stage, we performed a univariate analysis, using Student's t-test. In the second stage, we performed a multivariate analysis including only those OCT parameters that discriminated at a nominal level, between positive/negative biomarkers in stage 1.
RESULTS
We found significant differences between the OCT measurements of pTau- and tTau-positive individuals compared with those who were negative for these markers, most notably that the GCL and the RNFL were thinner in the former. In stage 2, our dependent variables were the quantitative values of CSF markers and the hippocampal volume. The Aβ 1-42/40 ratio did not show a significant correlation with OCT measurements while the associations between pTau and tTau with GCL were statistically significant, especially in the temporal region of the macula. Besides, the multivariate analysis showed a significant correlation between hippocampal volume with GCL and RNFL. However, after false discovery rate correction, only the associations with hippocampal volume remained significant.
CONCLUSIONS
We found a significant correlation between Tau (pTau) and neurodegeneration biomarkers (tTau and hippocampus volume) with GCL degeneration and, to a lesser degree, with damage in RFNL. OCT analysis constitutes a non-invasive and unexpensive biomarker that allows the detection of neurodegeneration in cognitively asymptomatic individuals.
Identifiants
pubmed: 35449033
doi: 10.1186/s13195-022-00998-6
pii: 10.1186/s13195-022-00998-6
pmc: PMC9022357
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
57Informations de copyright
© 2022. The Author(s).
Références
Clin Ophthalmol. 2016 Dec 05;10:2417-2425
pubmed: 27980390
Front Neurosci. 2020 Jul 31;14:758
pubmed: 32848548
Alzheimers Dement (N Y). 2019 Oct 09;5:570-578
pubmed: 31650013
Nat Commun. 2019 Sep 17;10(1):4227
pubmed: 31530809
Neurosci Lett. 2015 Jan 1;584:12-6
pubmed: 25451722
PLoS One. 2019 Sep 11;14(9):e0222347
pubmed: 31509597
Ann Neurol. 2016 Jan;79(1):110-9
pubmed: 26505746
Front Cell Neurosci. 2016 Feb 04;10:20
pubmed: 26869887
Alzheimers Dement (Amst). 2016 Oct 01;4:169-178
pubmed: 27830174
Eur J Neurol. 2021 Mar;28(3):763-774
pubmed: 33107159
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Lancet Neurol. 2009 Jul;8(7):619-27
pubmed: 19523877
Ophthalmology. 2019 Apr;126(4):497-510
pubmed: 30114417
J Alzheimers Dis. 2016 Sep 6;54(2):585-95
pubmed: 27567815
Neuroreport. 2011 Aug 24;22(12):623-7
pubmed: 21734608
J Clin Med. 2020 Jun 02;9(6):
pubmed: 32498362
Lancet Neurol. 2007 Aug;6(8):734-46
pubmed: 17616482
Alzheimers Res Ther. 2017 Mar 1;9(1):13
pubmed: 28253913
Alzheimers Dement. 2020 Nov;16(11):1553-1560
pubmed: 31706733
Invest Ophthalmol Vis Sci. 2014 Jan 29;55(1):523-34
pubmed: 24398104
J Neurol Sci. 2021 Jan 15;420:117213
pubmed: 33271374
Ann Neurol. 2016 Jan;79(1):90-109
pubmed: 26505992
Neurobiol Aging. 2017 Mar;51:141-147
pubmed: 28068565
Front Neurol. 2017 May 04;8:162
pubmed: 28522986
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
Eye (Lond). 2019 Nov;33(11):1741-1747
pubmed: 31164729
JAMA. 2009 Jul 22;302(4):385-93
pubmed: 19622817
J Alzheimers Dis. 2016 Nov 1;55(1):19-35
pubmed: 27662307
Cell Death Dis. 2018 Jun 7;9(6):685
pubmed: 29880901
Eur J Ophthalmol. 2018 Jan;28(1):42-46
pubmed: 28862734
Alzheimers Dement (Amst). 2018 Feb 07;10:196-209
pubmed: 29780864
J Neurosci. 2005 Aug 3;25(31):7278-87
pubmed: 16079410
J Alzheimers Dis. 2015;46(4):817-36
pubmed: 26402622
Eur J Neurol. 2020 Nov;27(11):2225-2232
pubmed: 32602573
Expert Opin Ther Pat. 2015 Apr;25(4):413-23
pubmed: 25746836
Acta Neuropathol Commun. 2020 Dec 7;8(1):216
pubmed: 33287900
Science. 1991 Nov 22;254(5035):1178-81
pubmed: 1957169
J Alzheimers Dis. 2020;73(3):1201-1209
pubmed: 31884473
PLoS One. 2016 Sep 06;11(9):e0162202
pubmed: 27598262
JCI Insight. 2017 Aug 17;2(16):
pubmed: 28814675
Ann Clin Transl Neurol. 2019 Sep;6(9):1815-1824
pubmed: 31464088
Alzheimers Dement (Amst). 2019 Jun 18;11:463-471
pubmed: 31249859
Brain. 2016 May;139(Pt 5):1551-67
pubmed: 26962052
J Alzheimers Dis. 2015;45(1):45-56
pubmed: 25428254
J Neurosci. 2015 Jul 22;35(29):10402-11
pubmed: 26203136
Acta Neuropathol. 2020 May;139(5):813-836
pubmed: 32043162
Korean J Ophthalmol. 2017 Dec;31(6):548-556
pubmed: 29022297
Neurology. 2020 Dec 8;95(23):e3104-e3116
pubmed: 32873693
Wiley Interdiscip Rev Syst Biol Med. 2009 Nov-Dec;1(3):380-389
pubmed: 20836003
PLoS One. 2012;7(12):e53547
pubmed: 23300938
Graefes Arch Clin Exp Ophthalmol. 2017 Sep;255(9):1827-1835
pubmed: 28643042
PLoS One. 2020 May 29;15(5):e0232785
pubmed: 32469871
PLoS One. 2020 Sep 21;15(9):e0239484
pubmed: 32956392
Neuroimage Clin. 2013 Mar 05;2:356-65
pubmed: 24179789
Neurology. 2016 Jun 14;86(24):2303-9
pubmed: 27225223
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494
Invest Ophthalmol Vis Sci. 2012 Sep 19;53(10):6301-2
pubmed: 22993249
Neuroimage. 2011 Jan;54 Suppl 1:S204-17
pubmed: 20550967
Arch Neurol. 2007 Mar;64(3):343-9
pubmed: 17210801
J Ophthalmol. 2016;2016:7291257
pubmed: 26925259